AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2004 JUN 3 - (NewsRx.com & NewsRx.net) -- Two new structural studies reveal how mutations within the C-terminal region of the BRCA1 protein affect the function of the BRCA1 gene, leading to breast cancer.
Among the 180,000 women who develop breast cancer each year, about 5% are due to inherited germline mutations in the breast cancer susceptibility gene product, BRCA1. BRCA1 plays a number of important roles in the cell including the response to DNA damage. Most of the inherited, early-onset breast cancers result from these mutations.
The C-terminal region of BRCA1 contains tandem repeats called BRCT domains that are generally thought to function as protein-protein interaction modules. Recent studies have shown that these repeats recognize phosphoserine or phosphothreonine (pSer or pThr) peptides, suggesting that some of the interactions of BRCA1 with other proteins may be regulated by protein phosphorylation.
Now, two groups have determined the structures of tandem BRCT repeats bound to phosphopeptides. The studies appear in the June 2004 issue of Nature Structural & Molecular Biology.
Michael Yaffe of the Massachusetts Institute of Technology and colleagues determined the crystal structure of this repeat domain bound to a phosphopeptide derived from Bach1, a known partner of BRCA1. The structure explains why tandem BRCT repeats, rather than single BRCT domains, are required for phosphopeptide ...
Source: HighBeam Research, Studies describe how mutations affect BRCA1 function.